Condition: Advanced Hepatocellular Carcinoma · Sponsor: Zhejiang University
A phase I clinical study of the safety and tolerability, efficacy of CNCT19 CAR T-cell therapy in patients with advanced hepatocellular carcinoma hepatocellular carcinoma.
This description comes directly from the study's public registry record.
Qi Zhang · Associate professor · qi.zhang@zju.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| First Affiliated Hospital, Medical College of Zhejiang University | Hangzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06676982